EC workshop on biosimilars focusses on sustainability

INICIO/Informes | Posted 10/01/2020 post-comment0 Post your comment

The European Commission (EC) held its fifth workshop on biosimilars in Brussels, Belgium on 30 October 2019. The focus of this workshop was the sustainability of the biosimilar medicines sector [1].

04 AA010978

Since 2010, a multi-stakeholder dialogue and co-operation at European level has been put in place under the Process on Corporate Responsibility/Access to Medicines in Europe including a Working Group on Market Access to and Uptake of Biosimilar Medicinal Products. The multi-stakeholder workshop held in Brussels was the fifth follow-up event to the activities related to biosimilars under the Process. The first in the series of annual workshops on biosimilars was organized by the EC in 2015.

The EC approved its first biosimilar Omnitrope (somatropin) back in 2006 [2]. Through its so-called ‘multi-stakeholder approach’ the EC (Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs) aims to build a common understanding and trust between doctors and patients, payers and the commercial operators.

A wide variety of participants representing patients, healthcare professionals, authorities and pharmaceutical industry companies shared experiences on the use of biologicals, including biosimilars. The discussions focused on policy choices and practices related to the uptake of biosimilars, in particular on the long-term sustainability of the biosimilar market.

As in previous years, IQVIA (formerly Quintiles & IMS Health) presented the updated 2019 report on the impact of biosimilar competition.

Related articles
Proposed policies to maximise societal benefit of biosimilars

Optimizing the benefits of biosimilars for society

1. European Commission Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs. Multi-stakeholder Workshop on Biosimilar Medicinal Products; 30 October 2019; Brussels, Belgium.
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Europe []. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Jan 10]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2020 Pro Pharma Communications International. All Rights Reserved.

Proposed policies to maximise societal benefit of biosimilars
comment icon Comments (0)
Post your comment
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010